RxDoctor Payments Data

Karen McGeehan, MD

Family Medicine · Virginia Beach, VANPI 1851366215

Payments from drug & device makers

$7,379in general payments, 2019–2025

Across 396 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$633
  • Pfizer$391
  • Otsuka America Pharmaceutical, Inc.$378
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$7,375100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,379 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$208,930
Medicare patients
558
Services billed
3,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$51,378
JardianceEmpagliflozin47$50,387
EliquisApixaban38$47,810
JanuviaSitagliptin Phosphate32$31,806
OzempicSemaglutide16$25,474
TrulicityDulaglutide19$24,348
RexultiBrexpiprazole12$20,136
MounjaroTirzepatide14$15,130
TradjentaLinagliptin12$12,399
Breo ElliptaFluticasone/Vilanterol17$11,610
MyrbetriqMirabegron16$8,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,595
Atorvastatin Calcium402$3,611
SymbicortBudesonide/Formoterol Fumarate11$3,286
Levothyroxine Sodium248$3,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$81$62,78659 claims
AstraZenecaFarxiga, Symbicort$1,349$54,66445 claims
PfizerEliquis$391$47,81038 claims
Lilly USA, LLCTrulicity, Mounjaro$633$39,47833 claims
MerckJanuvia$61$31,80632 claims
Novo NordiskOzempic$1,125$25,47416 claims
GSKBreo Ellipta, Trelegy Ellipta$310$20,20528 claims
Otsuka America Pharmaceutical, Inc.Rexulti$378$20,13612 claims
Astellas Pharma US IncMyrbetriq$77$8,68116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →